The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme

Abstract

BackgroundAustralia provided free quadrivalent human papillomavirus vaccines to 12–18-year-old girls and women aged ≤26 years from mid-2007 until the end of 2009. After this time, only girls aged 12–13 years had access to free vaccines.MethodsBefore and after the study, of the proportion of new patients attending Melbourne Sexual Health Centre from mid-2004 to mid-2011, diagnosed with genital warts (GW) by risk group.ResultsFrom July 2004 to June 2011, 52 454 new patients were seen at Melbourne Sexual Health Centre and 5021 (9.6%, 95% CI 9.3% to 9.8%) were diagnosed with GW. From July 2004 to June 2007, the proportions with GW either increased or did not change in all groups. Comparing the two 12-month periods of 2007/2008 and 2010/2011, GW declined in women under 21 years from 18.6% to 1.9% and in heterosexual men under 21 years from 22.9% to 2.9%. The ORs per year for diagnosis of GW adjusted for number of sexual partners from July 2007 until June 2011 in women and heterosexual men <21 years were 0.44 (95% CI 0.32 to 0.58) and 0.42 (95% CI 0.31 to 0.60), respectively. There was no significant change in GW in women ≥30 years (OR 0.97, 95% CI 0.84 to 1.12), heterosexual men ≥30 years (OR 0.97, 95% CI 0.89 to 1.06) or in homosexual men (OR 0.95, 95% CI 0.85 to 1.07).ConclusionThe dramatic decline and near disappearance of GW in women and men under 21 years of age, 4 years after commencing this programme, suggest that the basic reproductive rate has fallen below one.

Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa

“…24 Our observed safety findings are also similar to that of other studies, whereby vaccine recipients have higher rates of injection site pain, erythema and swelling, but similar rates of systemic AEs. 32 Given the high vaccine efficacy seen in the clinical trials, and the fact that in the 8 y since its original licensure, the qHPV vaccine has been shown to be highly effective at the population level, with marked reductions in the prevalence of HPV vaccine-type related infection and disease in many countries, [33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50] our findings suggest the vaccine should be equally effective in sub-Saharan African women.…”

Vaccins contre les papillomavirus humains (HPV)

“…Ce pays a en effet enregistré une forte diminution de l'incidence des condylomes chez les hommes, qui ne sont pourtant pas vaccinés [15,16]. Une vaccination avec un schéma simplifié, ne comportant que deux doses, pourrait améliorer la compliance tout en rédui-sant significativement les coûts [17].…”

“…DÉBAT FORUM d'efficacité contre les condylomes a été réalisée en 2011. Dans cette étude, le taux de condylomes chez les femmes âgées de moins de 21 ans consultant au Centre de santé sexuelle de Melbourne est passé de 19 % (avant l'arrivée du vaccin) à 1,9 % (en juin 2011) [16]. Le taux de condylomes chez les hommes hétérosexuels du même âge est passé de 17 % à 3 % pendant cette même période, alors qu'il n'a pas été modifié chez les homosexuels.…”

Vacunación contra virus papiloma humano: una experiencia chilena en atención primaria

“…La Atención Primaria de Quillota implementó el año 2011 un plan de vacunación contra el virus papiloma humano (VPH) 1 para la protección del cáncer cérvico-uterino 2 y enfermedades de transmisión sexual 3 . El objetivo fue posibilitar el acceso 4 a una estrategia de prevención primaria focalizada en población de riesgo 5 .…”